INTRODUCTION
Three types of joint disease are found in patients with cystic fibrosis (CF): hypertrophic pulmonary osteoarthropathy (HPOA) which is rare, at least in children, a remitting arthritis that is said to be unique to CF, the so-called CF arthritis, and other forms of joint disease that may happen to co-exist with CF1-3. The literature on joint disorders in CF mainly comprises case reports and case series. There have been no prospective studies of arthropathy in CF. Here we review the data currently available in English and French.
CLINICAL FEATURES
Hypertrophic pulmonary osteoarthropathy HPOA is characterized by finger clubbing, swelling of the distal parts of long bones and radiological evidence of alterations to the periosteum of long bones. Details of the radiological changes are given below. HPOA is currently thought to be due to the aggregation of megakaryocytes in the distal microcirculation4. Normally megakaryocytes are carried from the bone marrow to the pulmonary microcirculation. In the lungs, platelets are released when the cytoplasm is stripped from the megakaryocytes. It is hypothesized that a right to left shunt in the lungs would allow megakaryocytes to pass through the lungs without releasing their platelets. Megakaryocyte aggregation occurs in the microcirculation of the extremities. The hypothesis is that the cytoplasm of the megakaryocytes would be stripped out in the distal microcirculation, thus causing the release of platelets, in turn releasing platelet derived growth factor causing the vasodilatation and excessive growth that characterize HPOA. Clubbing of the digits is thought to result from less extreme cases of the same processes. Variation in severity may result from the extent of the shunt or differences in platelet function4.
We have employed a Medline search supplemented by checking through key journals. By this means we have found a total of 90 reported cases of HPOA in CF1"5-7. In these reports the diagnosis of HPOA was made by three different sets of criteria:
1 The presence of long bone tenderness and imaging evidence of periosteal elevation of the distal portion of long bones7. 2 The presence of finger clubbing, combined with symmetrical pain or swelling of the knee or ankle6. 3 Digital clubbing, thickening of the extremities, articular symptoms, such as pain or tenderness of the joints, peripheral neurovascular disorders (chronic erythema, localized areas of increased sweating, paraesthesia) with or without imaging evidence of bilateral subperiosteal new bone formation5.
Cases were ascertained in different ways, either by prospective survey6'7 or by retrospective questionnaire5. Some published cases were ascertained by a rheumatologist. It is not possible to calculate the median age of patients affected by HPOA from the data since some papers provide mean ages only. From data for 45 patients it is possible to calculate that the mean age of onset of radiologically proven HPOA. It was 19.5 years, but the age distribution is unknown. Of 56 patients with HPOA for whom the sex was reported, 38 patients were male and 18 were female. Since this subject was last reviewed at the Royal Society of Medicine1, three centres have reported their experience of HPOAS-7. In these reports, which provide estimates derived from selected samples, the proportion of patients who developed HPOA over the study period varied from 1 of 140 children over a 6 year study period', 10 of 250 adults (4 year study period)6, 11 of 533 adults and children (2 year study period)7 and 25 of 450 children and adults (4 year study period)5.
Symptoms labelled as HPOA started either as a dull bone pain6 or episodic joint pain7. From papers which described the joint distribution (54 patients, 120 joints) the following joints were involved: knee 43 These changes have been called periostitis or periostosis. In one study6 the changes were visible on plain X-ray of affected limbs in 9 of 10 patients. The tenth patient had evidence of new bone formation on isotopic bone scanning. One group reviewed radiographs taken for indications other than joint pain and found asymptomatic periostosis in 1 of 72 patients6.
One review found that 12 of 14 patients suffered from HPOA in tandem with deterioration in their lung disease1. Cohen et al. found that exacerbations of the arthropathy did not correspond to changes in lung function or pulmonary infection5. Dixey et al. found that joint symptoms got worse during respiratory exacerbations in 3 of 10 patients6. Rush et a]. report that pulmonary exacerbation and joint disease were 'often' associated and that appropriate therapy of infection led to an improvement in joint symptoms without giving figures for this7.
Cystic fibrosis arthropathy
We have found a total of 71 cases reported in English or French following a Medline search. The youngest reported patient was 5 years old6. It is not possible to calculate a median age from the published data. The mean age of all 71 reported cases is 13.6 years. Of those for whom the sex was reported, 28 were male and 26 female. Since 1986, five CF centres have reported their experience of CF arthro-pathyl16'7,9-1. In these selected populations the number of cases was 5 of 206 children over a period of one year10, 12 of 533 adults and children over a period of two years7, 4 of 140 children over a period of 6 years1, 12 of 250 adults over a period of four years6, 5 of 59 adults asked if they had ever had joint symptoms (mean age of patients at the time of recall was 19 years)9 and 8 of 54 children admitted during a 1 year periodl1.
Our impression is that joint pains develop over approximately 12-24 hours, although most authors do not comment on this. The pains have been described as debilitating or disabling by two groups69, and episodes lasted an average of 4 days6 and less than one week9. The symptoms disappeared completely between attacks in 36 of 42 patients. In the other six the initial presentation was of a persistent arthritis. Four of these patients were positive for rheumatoid factor7'11 and appeared to have a disease that was indistinguishable from juvenile chronic arthritis. In one study with 10 patients who presented with an episodic form, four progressed to a persistent synovitis which involved damage to periarticular structures in three7. One group reported an adult diagnosed as suffering from classic rheumatoid arthritis and another as suffering from ankylosing spondylitis, but did not include either in their patient group6. The presence or absence of fever was with CF arthropathy''11 . Those reporting cases have all mentioned that the differential diagnosis at presentation includes septic arthritis or cellulitis.
Culture of synovial fluid was reported for 10 cases and was negative in all of them. Microscopy of the synovial fluid was also reported in these 10 cases: in five cases no cells were seen in synovial fluid9' 1; in two cases of the 10, neutrophils predominated6' I0; in three cases of the 10, lymphocytes predominated7 10. When cells were seen, the cell count varied from 20 cells per ml of synovial fluid6 to 56 000 per ml of synovial fluid7.
The distribution of joint symptoms in CF arthropathy was described in 49 patients and 103 joints and was knee 35, ankle 17, wrist 14, elbow 9, shoulder 8, proximal interphalangeal 5, metatarsophalangeal 5, metacarpophalangeal 3, 'fingers' 2, hip 4, back 11,7,10,11.
In five patients there was an association between joint symptoms and the advent of a respiratory exacerbation. In 66 patients there was no temporal relationship between the appearance of joint lesions and pulmonary disease. The radiological appearances of affected joints were reported as normal in 61 of the 71 cases. Only one study has reported abnormalities on X-ray of affected joints7. These authors reported that soft tissue swelling or erosion was seen in four patients, mild periarticular osteopenia in five patients and joint narrowing in five patients (which implies loss of articular cartilage). Three of the patients with evidence of cartilage destruction had persistent joint symptoms and were positive for rheumatoid factor7.
Ultrasound and magnetic resonance imaging have been used to look for evidence of cartilage changes, particularly in the context of surveillance of fluoroquinolones. These investigations are accepted as sensitive tools for the detection of cartilage injury. For example in young dogs abnormalities on magnetic resonance imaging were found to correlate well with ciprofloxacin-induced cartilage da-mage12. However, CF arthropathy occurs in patients not taking fluoroquinolones and with no changes on magnetic resonance imaging or ultrasound13. Our experience so far suggests that magnetic resonance imaging adds no information beyond that obtained from history, examination and plain radiographs.
A total of 8 synovial biopsies have been reported from patients suffering from CF arthritis. In one case the biopsy was taken at the onset of steroid therapy and showed a red, vascular synovium, a number of granulomata and a lymphocytic infiltration with occasional multinucleated giant cells1. In other cases, there have been no significant inflammatory changes, with a mild synovitis in one case. Six biopsies have been studied using immunoflourescence. Of these three had deposits of IgG, IgM, or C3 on the intima of synovial blood vessels6'9' 1. One synovial biopsy has been reported in two series and was present in 10 of 17 patients Supplement No. 31 Volume 90 1 997, obtained from a patient suffering from HPOA. This showed IgM present on endothelial cells, granules of C3 on vessel walls and positive staining for fibrinogen6. This suggests that immunoglobulin deposition is either non-specific or plays a common role in the aetiology of CF arthritis and joint problems in HPOA. The elements of the complement system have been measured in 37 patients with CF arthropathy. Three of these patients had reduced levels of Clq(19-24%)1. One patient had reduced levels of C3 and C4 during an acute attack (C35.0g/l, normal 5.5-12.0 g/l; c$0.7, normal 1.0-4.5)9. Complement factors have been measured in 21 patients with HPOA. Of these patients 5 were reported to have low levels, (range 0.12-0.23 g/l, normal 0.25/0.75 g/1)6.
All of the studies have compared the mean predicted FEV1 of their CF arthritis group to the mean FEVy for their clinic and found no significant difference. In contrast each group that studied patients with radiologically proven HPOA found that the mean FEVy was significantly lower than in patients with other forms of joint pain (10%5, 22%7, 32%6). One group7 reported that 2 patients with CF arthritis had Raynaud's phenomenon.
Other types of joint disease
Other causes of joint disease have been found in people suffering from CF. One eight year old with CF and a chronic polyarthritis had sarcoidosis14. One of our original patients was later diagnosed as having a psoriatic arthropathy15. The possible role of circulating immune complexes in the pathogenesis of arthropathy in CF will be discussed below. Hyperuricosaemia has been documented in patients taking pancreatic supplements. Serum uric acid levels have been measured in 34 patients with CF arthropathy: all were within the normal range1'6 '9 Purpura A palpable purpuric rash has been described in a total of 39 patients with CF1"16-19. A palpable purpuric rash is described as pathognomonic of vasculitis20. Vasculitis can be involved in a range of disease processes. Some of these are disseminated and potentially fatal while others are restricted to skin and are self-limiting21. Some cases of vasculitis are associated with hypersensitivity either as part of an acute serum sickness-like illness or a more chronic condition2l. With respect to purpura in patients with CF, the patient's sex was reported in 28 cases: 14 were women, 14 were men. The reported mean age at onset is 19.3 years. The purpura affected the legs or feet in all cases. In one case the face was affected16. Biopsy of the purpura was performed in 15 cases in order to assess the extent of the inflammation and evaluate whether there were any similarities to other cases of vasculitis. All were reported adverse effects must be considered. This includes pancreatic supplements, ranitidine and antibiotics. two cases this was described as leucocytoclastic16'17.
Leucocytoclastic vasculitis has been reported in Henoch-Schonlein purpura and hypersensitivity vasculitis22. One patient with biopsy proven leucocytoclastic vasculitis for four months was taking ranitidine. The rash resolved when the ranitidine was stopped16. One patient died from cerebral vasculitis following an initial presentation with a purpuric rash. The rash resolved but the patient returned 10 days later. At this point he was seriously unwell with dyspnoea, haemoptysis and widespread purpura. He was treated with systemic corticosteroids but deteriorated and died following repeated fits. Post-mortem examination of his brain showed petechial haemorrhage, acute infarction and inflammation of blood vessels16. A previous paper reported that eight of nine patients died within two years of the onset of a palpable rash1. One group reported that the median survival after the appearance of a purpuric rash was 16 months (range 2 to 59 months, 13 deaths of 16 patients) 19 . This group provides no data concerning survival among patients unaffected by purpura. Other studies do not provide survival data. In two cases a diagnosis of Henoch-Schonlein purpura was made on the basis of findings at renal biopsy16'19. Two patients with CF and purpura have had cryoglobulinaemial6'17. The incidence of cryoglobulins in CF patients with no purpura is not known. Ten patients with CF purpura have been tested for anti-neutrophil cytoplasmic antibody (ANCA) and 4 were positive16. As a control group the authors also tested 61 patients matched by age, sex and microbiological flora. None of these were positive for these antibodies. ANCA can act as a marker for diseases associated with vasculitis that are not due to a hypersensitivity reaction. Cytoplasmic ANCA (C-ANCA) is directed against neutrophil proteinase 3 and is found in 90% of cases of Wegener' granulomatosis while perinuclear ANCA (P-ANCA) is found in a wider range of conditions including microscopic polyangiitis, Churg-Strauss vasculitis, pauci-immune glomerulonephritis and inflammatory bowel disease23. The incidence of the sub-types of ANCA in CF or CF purpura has not been reported.
There is some overlap between joint disease and skin disease in CF arthritis. Of 39 patients reported as having a purpuric rash, 18 have also had joint pain. Of 66 reported as having joint pain, 23 have also had a rash which was purpuric in 5 cases, described as erythema nodosum in 10 and an erythema over affected joints in the remainder.
THE PATHOGENESIS OF CYSTIC FIBROSIS ARTHRITIS
There have been many attempts to account for this clinical syndrome. The possibility that medication could have as showing an inflammatory process in the blood vessels. In The possible role of the immune system has been raised by many authors. We will consider evidence that CF could reflect either an abnormal activation of the immune system, or variation in the response provided by the immune system. Immune activation could be mediated by bacterial antigens, autoantigens or circulating immune complexes. Variation in the immune system is manifest, for example, in HLA types. In addition we will briefly discuss vasculitis.
Medication
In one report, one patient felt that his symptoms were due to pancreatic supplements and stopped them autono-mously3. The authors do not report what happened to the joint disease, or to the patient.
During pre-marketing trials of the fluoroquinolone antibiotics (e.g. ciprofloxacin, norfloxacin) it was noted that the administration of a single high dose was associated with abnormalities of the articular cartilage of immature animals24. This has led to caution in the use of these agents in children. In 35 day old rats toxicity 72 h after a single dose of ofloxacin is manifest by swelling of the cartilage matrix and fissuring of articular cartilage visible on light microscopy25. In one study rats were given a normal diet and a dose of ofloxacin in solution. Four doses were used: 0, 300, 600, 1200mg/kg. Each dose was given to seven rats. 600 mg/kg is nearly 100 times the usual starting dose in humans and gave rise to plasma levels ten times higher than those normally found in humans on therapeutic doses26. Another group was given a diet that was deficient in magnesium for seven days and then a dose of ofloxacin in solution. The same doses were used. None of 13 rats that were fed a normal diet and received 0 and 300 mg/kg of ofloxacin had cartilage lesions on light microscopy of a knee joint. Four of four rats fed a normal diet and given 1200mg/kg of ofloxacin had cartilage lesions on examination of a knee. Seven of seven rats given a low-magnesium diet and no ofloxacin had cartilage lesions on light microscopy of a knee. Eighteen of 18 rats given ofloxacin following a low-magnesium diet had cartilage lesions25. The authors report that the lesions seen following a lowmagnesium diet were indistinguishable from the lesions seen following a single dose of ofloxacin. This suggests that the lesions following large doses of ofloxacin may be due to low levels of magnesium in the articular cartilage. Quinolones chelate magnesium27. It has been suggested that cartilage lesions would be less likely to occur in fed human subjects who did not have magnesium deficiency.
One review of published reports found an incidence of 36 cases of reversible arthralgia out of 1 1 13 patients who had received ciprofloxacin28. The highest incidence of problems has been found in patients taking pefloxacin: nine arthropathy29. One adult has been reported to have an arthropathy that started with ciprofloxacin therapy, remitted when ciprofloxacin was withdrawn and returned when ciprofloxacin was used again30. Magnetic resonance imaging (MRI) has been used to investigate whether a course of ciprofloxacin is associated with cartilage damage. In 32 out of 32 patients no evidence of cartilage damage was found3l132. In one study 14 children who had received ofloxacin or ciprofloxacin were compared to 10 children who had not received either of these agents31. Arthralgia was reported in six of 14 children with CF who had received a quinolone and in four of 10 children with CF who had not received a quinolone. These authors reported that cartilage oedema was visible on MRI in five of 14 children with CF who had taken a quinolone antibiotic and in one of 10 who had not taken one of these agents. A suprapatellar joint effusion was seen in eight of 14 children with CF who had taken a quinolone -of these eight, three had joint symptoms. In children with CF who had not taken a quinolone six of 10 had a suprapatellar effusionof these three had joint symptoms31. The small numbers involved make it difficult to determine whether or not there was a difference in the incidence of the problems between the two groups. However, it is clear that in CF MRI abnormalities of the knee may be present in the absence of symptoms. The pathogenic mechanisms of arthralgia may be active in many patients.
A recent prospective randomized trial examined the use of ciprofloxacin in acute infective exacerbations in children13. This trial compared a course of oral ciprofloxacin to a course of intravenous ceftazidime and tobramycin (duration of treatment was 12 to 16 days). The incidence of musculoskeletal symptoms (including arthralgia, synovitis and tendon disorder) was 4 of 55 patients in the ciprofloxacin group and 6 of 53 patients in the group treated with ceftazidime and tobramycin13. Longterm follow up of five children with leukaemia who received norfloxacin for one month as an adjunct to a chemotherapy induction regimen found no evidence of joint effusion or cartilage damage as assessed by magnetic resonance imaging of the left knee. The median time of follow-up was 43 months33.
'Immune activation'

Provoking factors
The intense inflammation seen in lungs affected by CF leads to autolysis of immune cells. The presence of antibodies to neutrophil cytoplasmic elements in some patients with CF purpura has been mentioned above. Tests for antinuclear antibodies (ANA) have been reported in 42 cases of CF arthritis: three cases, all from the same study, were patients with CF out of 63 receiving this drug experienced Supplement No. 31 Volume 90 1 997 positive I 1. The incidence of ANA in the general CF population is not known. ANA have been described as 'the ESR of autoimmunity'34.
In addition to autoantigens, bacterial antigens could play a role. Finnegan et al. point out that direct search for bacterial antigens may not be productive because of the tendency for host defences to mask bacterial epitopes. They found evidence of staphylococcal antigen on immunofluorescence of skin biopsy tissue in one of the six patients with CF and vasculitis they tested for a range of bacterial antigens. This may represent passage ofbacterial components to the affected tissue. An alternative explanation has been advanced to account for reactive arthritis: an antigen-presenting cell which has incorporated antigen may give rise to a long-lived clone that continues to stimulate the immune system after the antigen itself has been cleared35.
Circulating immune complexes can trigger a cascade of inflammatory events which lead to tissue damage3. Circulating immune complexes are found in between 28% and 100% of CF patients37'38. There are several techniques for detecting circulating immune complexes and each can give different results, even in the same population (see Table 1 ). Some authors report that the level and frequency of circulating immune complexes rise during an infective exacerbation43. Others have been unable to confirm this finding38. There is evidence that the frequency of circulating immune complexes rises with age45. It has been suggested that circulating immune complexes may be a marker of disease progression or severity37'38. In a prospective study of 17 patients with CF over 15 months the presence of circulating immune complexes did not correlate with age, severity of disease, colonization with Pseudomonas aeruginosa, progression of disease or immune function as measured by white cell number and function, immunoglobulin levels or complement levels41.
Only one study has directly looked at the relationship between circulating immune complexes and remitting arthritis in CF11. In a group of young in-patients with CF seven out of seven children with signs of arthritis had circulating immune complexes at the time of the arthritis. In children without signs of arthritis one of 12 has circulating immune complexes. While this study suggests a link between circulating immune complexes and joint disease, the authors are unable to comment on how immune complexes relate to joint disease over time. Furthermore the patients studied may have been an atypical group. One child had an erosive disease; three had exacerbations of joint disease at the same time as infective exacerbation; one patient did not have a relapse during follow-up. Two other studies have measured circulating immune complexes in CF arthritis without measuring the incidence in a control group. Circulating immune complexes were found in two of 13 patients6 9.
Post-mortem studies on lung and kidney from CF patients have documented that deposition of immune complexes may occur in tissues that do not show evidence of an inflammatory response46'47. However, a weakness of these post-mortem studies is that damage may not be visible 44 Clq-binding 31 No relationship to HLA status or progression of disease *Patients who were stable, i.e. afebrile and with no clinical or laboratory indications of acute infection tPatients who had an infective exacerbation with fever, tachypnoea, sputum changes and X-ray changes because there may not have been enough time for inflammatory mechanisms to act after the deposition of the immune complexes. Antibodies to heat-shock proteins (heat shock proteins) 27 and 90 have been shown to be elevated in patients with CF arthritis when compared with CF patients without arthritis, and to be elevated in CF patients when compared with age and sex matched healthy controls48. Heat shock proteins are produced by a wide range of organisms in response to environmental stress, e.g. raised temperature at the bacterial level or infection at the human level. It is felt that heat shock proteins may have a role in enhancing inflammation for two reasons. First, they are highly conserved between bacteria and humans, and this could lead to confusion during an immune response. Secondly, they are themselves expressed as part of an inflammatory response and are associated with a particular class of cytolytic T cells. In normal circumstances heat shock proteins are tightly regulated. It is possible that a vicious circle could be set up in which infection leads to exposure which leads to breakdown of tolerance of self-heat shock proteins which leads to enhanced inflammation which leads to greater expression of heat shock proteins which leads to positive feedback49. Another study reported in abstract form suggested that there was an increase in the level of antibodies to members of the heat shock protein 60 family in the year prior to the onset of diabetes in patients with CF who developed diabetes mellitus50.
Evidence of immune activation
Reduced levels of factors of the complement system can indicate the presence of activation of the immune system, for example during serum sickness due to drug hypersensitivity51. Evidence of complement activation has been reported in a minority of cases of joint pain in CF (see above).
A current model for the pathogenesis of rheumatoid arthritis suggests that an initial presentation of antigen to Tcells is followed by activation of Band T-cell which leads onto accumulation of neutrophils, proliferation of synovium and alterations in nearby bone52. A similar process may be occurring in those few patients with CF arthritis who develop erosive disease either as an extreme version of a process that is present in all patients with CF arthritis or as a distinct process. It should be noted that erosive disease is a signal for aggressive anti-inflammatory management in RA. Processes of cell-mediated immune activation have not been widely studied in CF, nor have the reasons why such stimulation is successfully restrained in the majority of patients. Rheumatoid factor has been measured in 53 patients with CF arthritis and was positive in 1 1,3,4,6,7,1 1. people with CF without joint-disease usually associated with infective exacerbation53'54.
Variation in the immune system Variation in the major histocompatability complex as shown by human leucocyte antigen (HLA) status is likely to alter the handling of pathogens. For example, HLA-B27 has been shown to increase the risk of reactive arthritis. Recent work has refined this due to the description of subtypes of HLA types which affect antigen binding55. While some studies have analysed HLA status in CF arthritis, these were done some years ago and advances in this field may make this a worthwhile area to revisit. The idea of reactive arthritis in CF is suggested since there is a clear source of pathogens in many cases56. In a total of 18 patients reported there has been no abnormal pattern of HLA expression3 67. In particular, only two patients have been HLA B27 positive.
Vasculitis
Evidence that inflammation occurs within blood vessel walls in patients with CF has been presented. This has come from patients with skin rashes, although some of these have also had joint disease. Vasculitis may be the manifestation of hypersensitivity reaction to an identifiable antigen (as in serum sickness)51. Alternatively, vasculitis may be part of a connective tissue syndrome. Contemporary ideas about the pathogenesis of vasculitis that is not due to a clear hypersensitivity reaction invoke a complex array of forces involving autoimmunity, immune activation and endothelial defences57. Vasculitis can be a severe illness, particularly when it affects the brain16 58. It is possible that this condition is under-recognized. A vasculitis with similarities to that of CF is Henoch-Schonlein purpura. This is a vasculitis of the skin and other organs that is thought to be mediated by IgA. Many micro-organisms have been implicated in its causation22 but the links between exposure and symptoms remain obscure.
DISCUSSION
The initial diagnostic workup of joint problems will depend on the clinical presentation. In many cases it is necessary to perform a range of investigations to exclude pathologies unrelated to CF. If a single joint is involved with local tenderness a screen for septic causes should be carried out. This would involve a full blood count, measure of an acute phase reactant (erythrocyte sedimentation rate, ESR, or C reactive protein, CRP), and a plain radiograph of the affected joint. If there is clinical suspicion of septic arthritis, synovial fluid should be obtained. If synovial fluid is obtained then as well as microscopy and culture it should be examined for evidence of crystals by a laboratory Rheumatoid factor of various types has been found in Supplement No, 3 1 Vo u me 90 1 9 9 7 experienced in this. It may be helpful to perform tests for rheumatological disease including ANA (inc. anti ds-DNA for systemic lupus), rheumatoid factor, HLA B27 and uric acid. If a cause unrelated to CF can be excluded, the distinction between CF arthritis and HPOA can be made on clinical grounds or radiographically. People with CF arthritis tend to be generally well, with well preserved lung function and a sudden onset of joint disease. People with HPOA tend to have poorly preserved lung function and to have an insidious onset of bone pain as well as any joint pain. Evidence of periostosis on X-ray of distal portions of long bones is strong evidence in support of a diagnosis of HPOA.
Most cases of CF arthritis will resolve spontaneously. Treatment is limited to bed rest and nonsteroidal antiinflammatory agents. HPOA may be managed in the same way, in combination with vigorous therapy of any coexistent pulmonary infection. Evidence of erosive joint disease should prompt aggressive antiinflammatory therapy with agents such as corticosteroids under the direct supervision of an experienced rheumatologist in order to prevent permanent joint damage.
Evidence of vasculitis should prompt further investigations to assess the extent of tissue involvement. Histological examination of palpable purpura by a histopathologist with experience of examining inflamed blood vessels could be of value in defining typology and prognosis of this condition59. If there is any suggestion that the vasculitis represents a hypersensitivity phenomenon then there would be a thorough search for avoidable precipitants. Many drugs have been implicated in the induction of a vasculitis60. Baseline investigations would include full blood count, acute phase reactant (ESR or CRP), immunoglobulins, ANA, ANCA (subtypes), creatinine and electrolytes. Particular organs vulnerable to vasculitic damage must be investigated, depending on the clinical context. This could include brain (magnetic resonance imaging provides a non-invasive method with 50-100% specificity58) and kidneys (biopsy may be of value). As reported above the inflammatory process of uncontrolled vasculitis can be fatal16. It is possible that undertreatment of this condition is responsible for preventable deterioration in some patients with CF.
